Atara Biotherapeutics Inc (ATRA)

Atara Biotherapeutics' stock price has been significantly impacted by regulatory setbacks. The FDA rejected tabelecleucel (Ebvallo) for the second time in less than a year in January 2026, causing the stock to tumble 57% on the day of the announcement. The FDA's rejection was attributed to manufacturing issues and deficiencies in the ALLELE study. The stock price decreased by 27.34% in the past month and 13.77% over the last 12 months as of April 10, 2026.

There is no explicit information available regarding demand seasonality for Atara Biotherapeutics, Inc.'s products or services. Demand is typically driven by clinical need, regulatory approvals, and market access rather than seasonal patterns.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf, allogeneic T-cell immunotherapies for solid tumors, hematologic cancers, and autoimmune diseases. Their lead product candidate is Tabelecleucel (Tab-cel®), marketed as Ebvallo™ in approved regions, which is in Phase 3 clinical trials for the treatment of Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease (PTLD) and nasopharyngeal carcinoma. Atara has strategically narrowed its focus, pausing or discontinuing some programs to concentrate on Ebvallo's commercialization.

Atara Biotherapeutics, Inc. conducts its development and operational activities primarily in the United States, with headquarters in Thousand Oaks, California, and another facility in South San Francisco, California. Ebvallo has received marketing authorization in the European Economic Area (EEA), the United Kingdom, and Switzerland.

Atara Biotherapeutics' brand reputation has been significantly affected by the repeated regulatory challenges for its lead product, Ebvallo. The FDA's rejection of tabelecleucel in January 2026, citing manufacturing issues and study deficiencies, has been a major negative event. Securities fraud class action lawsuits have been announced against Atara Biotherapeutics, alleging that the company failed to disclose critical information regarding the unlikelihood of FDA approval for tabelecleucel.

The ownership structure of Atara Biotherapeutics (ATRA) includes institutional investors, insiders, and retail investors. Approximately 16.59% to 26.19% of the company's stock is held by institutional investors, while insiders own around 41.88%. Major institutional shareholders include EcoR1 Capital, LLC, Redmile Group, LLC, Vanguard Group Inc, Globeflex Capital L P, and BlackRock, Inc. Panacea Innovation Ltd is the largest individual shareholder, holding 32.47% of the company's shares.